Gold prices fall as geopolitical tensions ease; U.S. CPI looms
Cero Therapeutics Holdings, Inc. (NASDAQ:CERO) announced Monday that it has entered into a new purchase agreement with an institutional investor, allowing the company to issue and sell up to $17,490,897 of its common stock. The agreement, signed on Friday, continues the company’s equity line program, which began under previous agreements.
According to a press release statement and SEC filing, the new purchase agreement follows two prior stock purchase agreements dated February 14, 2024, and November 8, 2024. Under those agreements, Cero Therapeutics had issued and sold a total of 112,273 shares of common stock to the investor for aggregate proceeds of approximately $7.5 million as of June 30, 2025. The company’s financial health score is currently rated as WEAK by InvestingPro, with a concerning current ratio of 0.73.
The new agreement enables Cero Therapeutics to sell additional shares to the investor, up to the specified dollar limit, minus any further proceeds from the November 2024 agreement after June 30, 2025. The company may, at its discretion, direct the investor to purchase shares on any business day when the stock’s closing price is at least $0.01. Each individual purchase is limited to the lower of 10,000 shares or $100,000 per transaction. The agreement also includes provisions for volume-weighted average price (VWAP) purchases, with a maximum aggregate commitment of $10 million for these transactions on any given day.
The agreement restricts the investor’s ownership to no more than 4.99% of Cero Therapeutics’ outstanding common stock at any time. Concurrently, Cero Therapeutics entered into a registration rights agreement with the investor, providing customary registration rights for shares issued under the agreement.
Cero Therapeutics’ common stock is listed on the NASDAQ Global Market under the ticker CERO, and its warrants are listed on the NASDAQ Capital Market under the ticker CEROW.
All information is based on a press release statement and the company’s recent filing with the U.S. Securities and Exchange Commission.
In other recent news, Cero Therapeutics Holdings, Inc. has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company had previously faced potential delisting after its stock price fell below the required minimum for 30 consecutive business days, but it successfully appealed the decision. Additionally, Cero Therapeutics has expanded its investor base by amending its securities purchase agreement to include new institutional investors in its Series D preferred stock sale. This move has resulted in gross proceeds of approximately $1,852,000 from the recent issuance of 2,315 shares.
D. Boral (OTC:BOALY) Capital has upgraded Cero Therapeutics’ stock rating from Hold to Buy, citing confidence in the company’s innovative T cell engineering approach for solid tumors. The upgrade comes with a price target of $30.00 and highlights the company’s Chimeric Engulfment Receptor technology as a potential catalyst for stock appreciation. Furthermore, the U.S. Food and Drug Administration has granted Orphan Drug Designation to Cero’s lead candidate CER-1236 for the treatment of acute myeloid leukemia (AML). This designation offers several benefits, including assistance in clinical trial design and potential marketing exclusivity for seven years if approved. CER-1236 is currently undergoing Phase 1 clinical trials to evaluate its safety and efficacy in AML patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.